nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—ADRB2—prostate cancer	0.471	1	CbGaD
Phenylpropanolamine—CYP1A2—Flutamide—prostate cancer	0.0495	0.347	CbGbCtD
Phenylpropanolamine—CYP1A2—Estrone—prostate cancer	0.0358	0.251	CbGbCtD
Phenylpropanolamine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0234	0.164	CbGbCtD
Phenylpropanolamine—CYP1A2—Estradiol—prostate cancer	0.0206	0.144	CbGbCtD
Phenylpropanolamine—CYP1A2—Etoposide—prostate cancer	0.0134	0.094	CbGbCtD
Phenylpropanolamine—Phenelzine—CYP3A43—prostate cancer	0.00122	0.147	CrCbGaD
Phenylpropanolamine—CYP1A2—urine—prostate cancer	0.00112	0.16	CbGeAlD
Phenylpropanolamine—Pseudoephedrine—IL2—prostate cancer	0.000942	0.113	CrCbGaD
Phenylpropanolamine—L-Phenylalanine—TH—prostate cancer	0.000784	0.0941	CrCbGaD
Phenylpropanolamine—Feeling abnormal—Cabazitaxel—prostate cancer	0.000741	0.004	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.00074	0.00399	CcSEcCtD
Phenylpropanolamine—Rash—Abiraterone—prostate cancer	0.000738	0.00398	CcSEcCtD
Phenylpropanolamine—Dermatitis—Abiraterone—prostate cancer	0.000737	0.00398	CcSEcCtD
Phenylpropanolamine—Ephedrine—ACHE—prostate cancer	0.000736	0.0883	CrCbGaD
Phenylpropanolamine—Vomiting—Estrone—prostate cancer	0.000732	0.00395	CcSEcCtD
Phenylpropanolamine—Rash—Estrone—prostate cancer	0.000725	0.00392	CcSEcCtD
Phenylpropanolamine—Dermatitis—Estrone—prostate cancer	0.000725	0.00391	CcSEcCtD
Phenylpropanolamine—Nausea—Estramustine—prostate cancer	0.000715	0.00386	CcSEcCtD
Phenylpropanolamine—Dizziness—Nilutamide—prostate cancer	0.000707	0.00382	CcSEcCtD
Phenylpropanolamine—Dizziness—Flutamide—prostate cancer	0.000704	0.0038	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Degarelix—prostate cancer	0.000703	0.0038	CcSEcCtD
Phenylpropanolamine—Insomnia—Bicalutamide—prostate cancer	0.000698	0.00377	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Bicalutamide—prostate cancer	0.000688	0.00371	CcSEcCtD
Phenylpropanolamine—Somnolence—Bicalutamide—prostate cancer	0.000686	0.0037	CcSEcCtD
Phenylpropanolamine—Nausea—Estrone—prostate cancer	0.000683	0.00369	CcSEcCtD
Phenylpropanolamine—Vomiting—Nilutamide—prostate cancer	0.00068	0.00367	CcSEcCtD
Phenylpropanolamine—Anxiety—Ethinyl Estradiol—prostate cancer	0.000678	0.00366	CcSEcCtD
Phenylpropanolamine—Vomiting—Flutamide—prostate cancer	0.000676	0.00365	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Goserelin—prostate cancer	0.000675	0.00364	CcSEcCtD
Phenylpropanolamine—Rash—Nilutamide—prostate cancer	0.000674	0.00364	CcSEcCtD
Phenylpropanolamine—Dermatitis—Nilutamide—prostate cancer	0.000673	0.00364	CcSEcCtD
Phenylpropanolamine—Rash—Flutamide—prostate cancer	0.000671	0.00362	CcSEcCtD
Phenylpropanolamine—Dermatitis—Flutamide—prostate cancer	0.00067	0.00362	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Conjugated Estrogens—prostate cancer	0.000668	0.00361	CcSEcCtD
Phenylpropanolamine—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000664	0.00359	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Cabazitaxel—prostate cancer	0.000663	0.00358	CcSEcCtD
Phenylpropanolamine—Constipation—Bicalutamide—prostate cancer	0.00066	0.00356	CcSEcCtD
Phenylpropanolamine—Tension—Goserelin—prostate cancer	0.000645	0.00348	CcSEcCtD
Phenylpropanolamine—Tension—Conjugated Estrogens—prostate cancer	0.000639	0.00345	CcSEcCtD
Phenylpropanolamine—Nervousness—Goserelin—prostate cancer	0.000639	0.00345	CcSEcCtD
Phenylpropanolamine—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000638	0.00345	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Bicalutamide—prostate cancer	0.000636	0.00343	CcSEcCtD
Phenylpropanolamine—Nausea—Nilutamide—prostate cancer	0.000635	0.00343	CcSEcCtD
Phenylpropanolamine—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000633	0.00342	CcSEcCtD
Phenylpropanolamine—Nervousness—Conjugated Estrogens—prostate cancer	0.000633	0.00342	CcSEcCtD
Phenylpropanolamine—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000633	0.00342	CcSEcCtD
Phenylpropanolamine—Nausea—Flutamide—prostate cancer	0.000632	0.00341	CcSEcCtD
Phenylpropanolamine—Dizziness—Degarelix—prostate cancer	0.000631	0.00341	CcSEcCtD
Phenylpropanolamine—Drowsiness—Mitoxantrone—prostate cancer	0.000622	0.00336	CcSEcCtD
Phenylpropanolamine—Vision blurred—Goserelin—prostate cancer	0.00062	0.00335	CcSEcCtD
Phenylpropanolamine—Liver injury—Epirubicin—prostate cancer	0.000616	0.00332	CcSEcCtD
Phenylpropanolamine—Vision blurred—Conjugated Estrogens—prostate cancer	0.000614	0.00331	CcSEcCtD
Phenylpropanolamine—ADRB1—prostate gland—prostate cancer	0.000613	0.088	CbGeAlD
Phenylpropanolamine—Vomiting—Degarelix—prostate cancer	0.000607	0.00328	CcSEcCtD
Phenylpropanolamine—Rash—Degarelix—prostate cancer	0.000602	0.00325	CcSEcCtD
Phenylpropanolamine—Dermatitis—Degarelix—prostate cancer	0.000601	0.00325	CcSEcCtD
Phenylpropanolamine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000596	0.00322	CcSEcCtD
Phenylpropanolamine—Dizziness—Cabazitaxel—prostate cancer	0.000595	0.00321	CcSEcCtD
Phenylpropanolamine—Vomiting—Cabazitaxel—prostate cancer	0.000572	0.00309	CcSEcCtD
Phenylpropanolamine—Liver injury—Doxorubicin—prostate cancer	0.00057	0.00308	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Prednisone—prostate cancer	0.000569	0.00307	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Bicalutamide—prostate cancer	0.000568	0.00307	CcSEcCtD
Phenylpropanolamine—Nausea—Degarelix—prostate cancer	0.000567	0.00306	CcSEcCtD
Phenylpropanolamine—Anxiety—Goserelin—prostate cancer	0.000558	0.00301	CcSEcCtD
Phenylpropanolamine—Constipation—Ethinyl Estradiol—prostate cancer	0.000558	0.00301	CcSEcCtD
Phenylpropanolamine—Flushing—Estradiol—prostate cancer	0.000556	0.003	CcSEcCtD
Phenylpropanolamine—Anxiety—Conjugated Estrogens—prostate cancer	0.000553	0.00298	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Epirubicin—prostate cancer	0.000551	0.00298	CcSEcCtD
Phenylpropanolamine—Confusional state—Goserelin—prostate cancer	0.000541	0.00292	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.000537	0.0029	CcSEcCtD
Phenylpropanolamine—Nausea—Cabazitaxel—prostate cancer	0.000534	0.00288	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Epirubicin—prostate cancer	0.000528	0.00285	CcSEcCtD
Phenylpropanolamine—Ataxia—Docetaxel—prostate cancer	0.000524	0.00283	CcSEcCtD
Phenylpropanolamine—Tachycardia—Goserelin—prostate cancer	0.000524	0.00283	CcSEcCtD
Phenylpropanolamine—Tachycardia—Conjugated Estrogens—prostate cancer	0.000519	0.0028	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Epirubicin—prostate cancer	0.000518	0.0028	CcSEcCtD
Phenylpropanolamine—Irritability—Capecitabine—prostate cancer	0.000515	0.00278	CcSEcCtD
Phenylpropanolamine—Urinary retention—Capecitabine—prostate cancer	0.000513	0.00277	CcSEcCtD
Phenylpropanolamine—Tension—Estradiol—prostate cancer	0.000512	0.00276	CcSEcCtD
Phenylpropanolamine—Dizziness—Bicalutamide—prostate cancer	0.00051	0.00275	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Doxorubicin—prostate cancer	0.00051	0.00275	CcSEcCtD
Phenylpropanolamine—Ataxia—Capecitabine—prostate cancer	0.000508	0.00274	CcSEcCtD
Phenylpropanolamine—Nervousness—Estradiol—prostate cancer	0.000506	0.00273	CcSEcCtD
Phenylpropanolamine—Hypotension—Goserelin—prostate cancer	0.000502	0.00271	CcSEcCtD
Phenylpropanolamine—Amphetamine—SLC22A3—prostate cancer	0.0005	0.06	CrCbGaD
Phenylpropanolamine—Arrhythmia—Mitoxantrone—prostate cancer	0.000498	0.00269	CcSEcCtD
Phenylpropanolamine—Hypotension—Conjugated Estrogens—prostate cancer	0.000497	0.00268	CcSEcCtD
Phenylpropanolamine—Vomiting—Bicalutamide—prostate cancer	0.000491	0.00265	CcSEcCtD
Phenylpropanolamine—Tremor—Estradiol—prostate cancer	0.000488	0.00264	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—prostate cancer	0.000488	0.00264	CcSEcCtD
Phenylpropanolamine—Rash—Bicalutamide—prostate cancer	0.000486	0.00263	CcSEcCtD
Phenylpropanolamine—Dermatitis—Bicalutamide—prostate cancer	0.000486	0.00262	CcSEcCtD
Phenylpropanolamine—Insomnia—Goserelin—prostate cancer	0.000485	0.00262	CcSEcCtD
Phenylpropanolamine—ADRA1A—prostate gland—prostate cancer	0.000485	0.0696	CbGeAlD
Phenylpropanolamine—Insomnia—Conjugated Estrogens—prostate cancer	0.000481	0.0026	CcSEcCtD
Phenylpropanolamine—MAOA—prostate gland—prostate cancer	0.000481	0.069	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00048	0.00259	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—prostate cancer	0.000479	0.00259	CcSEcCtD
Phenylpropanolamine—Agitation—Estradiol—prostate cancer	0.000479	0.00259	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Goserelin—prostate cancer	0.000478	0.00258	CcSEcCtD
Phenylpropanolamine—Somnolence—Goserelin—prostate cancer	0.000477	0.00258	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000474	0.00256	CcSEcCtD
Phenylpropanolamine—Somnolence—Conjugated Estrogens—prostate cancer	0.000473	0.00255	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Prednisone—prostate cancer	0.00047	0.00254	CcSEcCtD
Phenylpropanolamine—Methamphetamine—SLC22A3—prostate cancer	0.000463	0.0556	CrCbGaD
Phenylpropanolamine—Irritability—Prednisone—prostate cancer	0.000459	0.00248	CcSEcCtD
Phenylpropanolamine—Constipation—Goserelin—prostate cancer	0.000459	0.00248	CcSEcCtD
Phenylpropanolamine—Nausea—Bicalutamide—prostate cancer	0.000458	0.00247	CcSEcCtD
Phenylpropanolamine—Vision blurred—Mitoxantrone—prostate cancer	0.000458	0.00247	CcSEcCtD
Phenylpropanolamine—Constipation—Conjugated Estrogens—prostate cancer	0.000455	0.00245	CcSEcCtD
Phenylpropanolamine—Anxiety—Estradiol—prostate cancer	0.000442	0.00239	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Goserelin—prostate cancer	0.000442	0.00239	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2A6—prostate cancer	0.000434	0.0521	CrCbGaD
Phenylpropanolamine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000431	0.00233	CcSEcCtD
Phenylpropanolamine—Flushing—Etoposide—prostate cancer	0.000431	0.00233	CcSEcCtD
Phenylpropanolamine—Confusional state—Estradiol—prostate cancer	0.000429	0.00232	CcSEcCtD
Phenylpropanolamine—Tachycardia—Estradiol—prostate cancer	0.000415	0.00224	CcSEcCtD
Phenylpropanolamine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000415	0.00224	CcSEcCtD
Phenylpropanolamine—Anxiety—Mitoxantrone—prostate cancer	0.000412	0.00223	CcSEcCtD
Phenylpropanolamine—Rash—Ethinyl Estradiol—prostate cancer	0.000411	0.00222	CcSEcCtD
Phenylpropanolamine—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000411	0.00222	CcSEcCtD
Phenylpropanolamine—MAOA—seminal vesicle—prostate cancer	0.000406	0.0584	CbGeAlD
Phenylpropanolamine—Confusional state—Mitoxantrone—prostate cancer	0.0004	0.00216	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Goserelin—prostate cancer	0.000395	0.00214	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000392	0.00211	CcSEcCtD
Phenylpropanolamine—Nausea—Ethinyl Estradiol—prostate cancer	0.000387	0.00209	CcSEcCtD
Phenylpropanolamine—Tachycardia—Mitoxantrone—prostate cancer	0.000387	0.00209	CcSEcCtD
Phenylpropanolamine—Insomnia—Estradiol—prostate cancer	0.000385	0.00208	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Estradiol—prostate cancer	0.000379	0.00205	CcSEcCtD
Phenylpropanolamine—Somnolence—Estradiol—prostate cancer	0.000378	0.00204	CcSEcCtD
Phenylpropanolamine—Ephedrine—ADRB2—prostate cancer	0.000372	0.0446	CrCbGaD
Phenylpropanolamine—Hypotension—Mitoxantrone—prostate cancer	0.00037	0.002	CcSEcCtD
Phenylpropanolamine—ADRA2A—prostate gland—prostate cancer	0.000369	0.0529	CbGeAlD
Phenylpropanolamine—Constipation—Estradiol—prostate cancer	0.000364	0.00196	CcSEcCtD
Phenylpropanolamine—Flushing—Docetaxel—prostate cancer	0.000358	0.00193	CcSEcCtD
Phenylpropanolamine—ADRA1A—epithelium—prostate cancer	0.000356	0.0512	CbGeAlD
Phenylpropanolamine—Dizziness—Goserelin—prostate cancer	0.000355	0.00192	CcSEcCtD
Phenylpropanolamine—Ataxia—Epirubicin—prostate cancer	0.000354	0.00191	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mitoxantrone—prostate cancer	0.000353	0.00191	CcSEcCtD
Phenylpropanolamine—Somnolence—Mitoxantrone—prostate cancer	0.000352	0.0019	CcSEcCtD
Phenylpropanolamine—Dizziness—Conjugated Estrogens—prostate cancer	0.000352	0.0019	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Estradiol—prostate cancer	0.000351	0.00189	CcSEcCtD
Phenylpropanolamine—Flushing—Capecitabine—prostate cancer	0.000347	0.00187	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Docetaxel—prostate cancer	0.000345	0.00186	CcSEcCtD
Phenylpropanolamine—Vomiting—Goserelin—prostate cancer	0.000341	0.00184	CcSEcCtD
Phenylpropanolamine—Constipation—Mitoxantrone—prostate cancer	0.000339	0.00183	CcSEcCtD
Phenylpropanolamine—Rash—Goserelin—prostate cancer	0.000338	0.00183	CcSEcCtD
Phenylpropanolamine—Dermatitis—Goserelin—prostate cancer	0.000338	0.00183	CcSEcCtD
Phenylpropanolamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000338	0.00183	CcSEcCtD
Phenylpropanolamine—Rash—Conjugated Estrogens—prostate cancer	0.000335	0.00181	CcSEcCtD
Phenylpropanolamine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000335	0.00181	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Capecitabine—prostate cancer	0.000334	0.0018	CcSEcCtD
Phenylpropanolamine—Confusional state—Etoposide—prostate cancer	0.000332	0.0018	CcSEcCtD
Phenylpropanolamine—Hallucination—Prednisone—prostate cancer	0.000331	0.00179	CcSEcCtD
Phenylpropanolamine—ADRA1A—renal system—prostate cancer	0.00033	0.0475	CbGeAlD
Phenylpropanolamine—MAOA—renal system—prostate cancer	0.000328	0.047	CbGeAlD
Phenylpropanolamine—Ataxia—Doxorubicin—prostate cancer	0.000327	0.00177	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000327	0.00176	CcSEcCtD
Phenylpropanolamine—Tachycardia—Etoposide—prostate cancer	0.000322	0.00174	CcSEcCtD
Phenylpropanolamine—MAOA—urethra—prostate cancer	0.000322	0.0462	CbGeAlD
Phenylpropanolamine—Nausea—Goserelin—prostate cancer	0.000319	0.00172	CcSEcCtD
Phenylpropanolamine—Nausea—Conjugated Estrogens—prostate cancer	0.000316	0.00171	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Estradiol—prostate cancer	0.000313	0.00169	CcSEcCtD
Phenylpropanolamine—ADRA2A—seminal vesicle—prostate cancer	0.000312	0.0448	CbGeAlD
Phenylpropanolamine—Flushing—Prednisone—prostate cancer	0.000309	0.00167	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2E1—prostate cancer	0.000308	0.037	CrCbGaD
Phenylpropanolamine—Hypotension—Etoposide—prostate cancer	0.000308	0.00166	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP3A5—prostate cancer	0.000307	0.0368	CrCbGaD
Phenylpropanolamine—Vision blurred—Capecitabine—prostate cancer	0.000306	0.00165	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2C19—prostate cancer	0.000305	0.0366	CrCbGaD
Phenylpropanolamine—Tremor—Capecitabine—prostate cancer	0.000305	0.00164	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Prednisone—prostate cancer	0.000297	0.0016	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Etoposide—prostate cancer	0.000294	0.00159	CcSEcCtD
Phenylpropanolamine—Somnolence—Etoposide—prostate cancer	0.000293	0.00158	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000292	0.00158	CcSEcCtD
Phenylpropanolamine—Drowsiness—Epirubicin—prostate cancer	0.00029	0.00156	CcSEcCtD
Phenylpropanolamine—SLC6A3—testis—prostate cancer	0.000285	0.0409	CbGeAlD
Phenylpropanolamine—Constipation—Etoposide—prostate cancer	0.000282	0.00152	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—ADRB2—prostate cancer	0.000282	0.0338	CrCbGaD
Phenylpropanolamine—Dizziness—Estradiol—prostate cancer	0.000281	0.00152	CcSEcCtD
Phenylpropanolamine—Amphetamine—CYP2A6—prostate cancer	0.00028	0.0336	CrCbGaD
Phenylpropanolamine—Confusional state—Docetaxel—prostate cancer	0.000276	0.00149	CcSEcCtD
Phenylpropanolamine—Anxiety—Capecitabine—prostate cancer	0.000276	0.00149	CcSEcCtD
Phenylpropanolamine—CYP1A2—renal system—prostate cancer	0.000273	0.0392	CbGeAlD
Phenylpropanolamine—Vision blurred—Prednisone—prostate cancer	0.000273	0.00147	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Etoposide—prostate cancer	0.000272	0.00147	CcSEcCtD
Phenylpropanolamine—Vomiting—Estradiol—prostate cancer	0.000271	0.00146	CcSEcCtD
Phenylpropanolamine—Rash—Estradiol—prostate cancer	0.000268	0.00145	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—prostate cancer	0.000268	0.00145	CcSEcCtD
Phenylpropanolamine—Dermatitis—Estradiol—prostate cancer	0.000268	0.00145	CcSEcCtD
Phenylpropanolamine—Confusional state—Capecitabine—prostate cancer	0.000268	0.00144	CcSEcCtD
Phenylpropanolamine—Tachycardia—Docetaxel—prostate cancer	0.000267	0.00144	CcSEcCtD
Phenylpropanolamine—Agitation—Prednisone—prostate cancer	0.000266	0.00144	CcSEcCtD
Phenylpropanolamine—Tachycardia—Capecitabine—prostate cancer	0.000259	0.0014	CcSEcCtD
Phenylpropanolamine—Hypotension—Docetaxel—prostate cancer	0.000256	0.00138	CcSEcCtD
Phenylpropanolamine—Nausea—Estradiol—prostate cancer	0.000253	0.00136	CcSEcCtD
Phenylpropanolamine—Vomiting—Mitoxantrone—prostate cancer	0.000252	0.00136	CcSEcCtD
Phenylpropanolamine—Rash—Mitoxantrone—prostate cancer	0.00025	0.00135	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mitoxantrone—prostate cancer	0.00025	0.00135	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP2E1—prostate cancer	0.000249	0.0299	CrCbGaD
Phenylpropanolamine—Hypotension—Capecitabine—prostate cancer	0.000248	0.00134	CcSEcCtD
Phenylpropanolamine—Insomnia—Docetaxel—prostate cancer	0.000248	0.00134	CcSEcCtD
Phenylpropanolamine—ADRA2A—urethra—prostate cancer	0.000247	0.0354	CbGeAlD
Phenylpropanolamine—Benzyl alcohol—CYP1A1—prostate cancer	0.000246	0.0295	CrCbGaD
Phenylpropanolamine—Anxiety—Prednisone—prostate cancer	0.000246	0.00133	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Docetaxel—prostate cancer	0.000244	0.00132	CcSEcCtD
Phenylpropanolamine—Somnolence—Docetaxel—prostate cancer	0.000244	0.00132	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Etoposide—prostate cancer	0.000243	0.00131	CcSEcCtD
Phenylpropanolamine—Flushing—Epirubicin—prostate cancer	0.000241	0.0013	CcSEcCtD
Phenylpropanolamine—Insomnia—Capecitabine—prostate cancer	0.00024	0.0013	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Capecitabine—prostate cancer	0.000237	0.00128	CcSEcCtD
Phenylpropanolamine—Nausea—Mitoxantrone—prostate cancer	0.000235	0.00127	CcSEcCtD
Phenylpropanolamine—Constipation—Docetaxel—prostate cancer	0.000234	0.00127	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Epirubicin—prostate cancer	0.000232	0.00125	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisone—prostate cancer	0.000231	0.00125	CcSEcCtD
Phenylpropanolamine—SLC6A2—testis—prostate cancer	0.00023	0.033	CbGeAlD
Phenylpropanolamine—Constipation—Capecitabine—prostate cancer	0.000227	0.00123	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Docetaxel—prostate cancer	0.000226	0.00122	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—prostate cancer	0.000223	0.00121	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—prostate cancer	0.000222	0.0012	CcSEcCtD
Phenylpropanolamine—Nervousness—Epirubicin—prostate cancer	0.00022	0.00119	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Capecitabine—prostate cancer	0.000219	0.00118	CcSEcCtD
Phenylpropanolamine—Dizziness—Etoposide—prostate cancer	0.000218	0.00118	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—prostate cancer	0.000215	0.00116	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisone—prostate cancer	0.000214	0.00115	CcSEcCtD
Phenylpropanolamine—Vision blurred—Epirubicin—prostate cancer	0.000213	0.00115	CcSEcCtD
Phenylpropanolamine—MAOA—testis—prostate cancer	0.000212	0.0304	CbGeAlD
Phenylpropanolamine—Phenelzine—CYP2E1—prostate cancer	0.000211	0.0253	CrCbGaD
Phenylpropanolamine—Vomiting—Etoposide—prostate cancer	0.00021	0.00113	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP2C19—prostate cancer	0.000209	0.025	CrCbGaD
Phenylpropanolamine—Agitation—Epirubicin—prostate cancer	0.000208	0.00112	CcSEcCtD
Phenylpropanolamine—Rash—Etoposide—prostate cancer	0.000208	0.00112	CcSEcCtD
Phenylpropanolamine—Dermatitis—Etoposide—prostate cancer	0.000208	0.00112	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—prostate cancer	0.000206	0.00111	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—prostate cancer	0.000204	0.0011	CcSEcCtD
Phenylpropanolamine—Constipation—Prednisone—prostate cancer	0.000202	0.00109	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Docetaxel—prostate cancer	0.000202	0.00109	CcSEcCtD
Phenylpropanolamine—Vision blurred—Doxorubicin—prostate cancer	0.000197	0.00107	CcSEcCtD
Phenylpropanolamine—Nausea—Etoposide—prostate cancer	0.000196	0.00106	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Capecitabine—prostate cancer	0.000195	0.00106	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisone—prostate cancer	0.000195	0.00105	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP3A4—prostate cancer	0.000194	0.0233	CrCbGaD
Phenylpropanolamine—Agitation—Doxorubicin—prostate cancer	0.000193	0.00104	CcSEcCtD
Phenylpropanolamine—Anxiety—Epirubicin—prostate cancer	0.000192	0.00104	CcSEcCtD
Phenylpropanolamine—Confusional state—Epirubicin—prostate cancer	0.000186	0.00101	CcSEcCtD
Phenylpropanolamine—Dizziness—Docetaxel—prostate cancer	0.000181	0.000979	CcSEcCtD
Phenylpropanolamine—Tachycardia—Epirubicin—prostate cancer	0.00018	0.000974	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—prostate cancer	0.000178	0.00096	CcSEcCtD
Phenylpropanolamine—Dizziness—Capecitabine—prostate cancer	0.000175	0.000947	CcSEcCtD
Phenylpropanolamine—Vomiting—Docetaxel—prostate cancer	0.000174	0.000941	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisone—prostate cancer	0.000174	0.00094	CcSEcCtD
Phenylpropanolamine—Rash—Docetaxel—prostate cancer	0.000173	0.000933	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—prostate cancer	0.000173	0.000933	CcSEcCtD
Phenylpropanolamine—Dermatitis—Docetaxel—prostate cancer	0.000173	0.000932	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—prostate cancer	0.000172	0.000931	CcSEcCtD
Phenylpropanolamine—Vomiting—Capecitabine—prostate cancer	0.000169	0.000911	CcSEcCtD
Phenylpropanolamine—Rash—Capecitabine—prostate cancer	0.000167	0.000903	CcSEcCtD
Phenylpropanolamine—Insomnia—Epirubicin—prostate cancer	0.000167	0.000903	CcSEcCtD
Phenylpropanolamine—Dermatitis—Capecitabine—prostate cancer	0.000167	0.000902	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—prostate cancer	0.000167	0.000901	CcSEcCtD
Phenylpropanolamine—SLC6A2—lymph node—prostate cancer	0.000167	0.0239	CbGeAlD
Phenylpropanolamine—Dyspnoea—Epirubicin—prostate cancer	0.000165	0.00089	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—prostate cancer	0.000164	0.000887	CcSEcCtD
Phenylpropanolamine—Nausea—Docetaxel—prostate cancer	0.000163	0.000879	CcSEcCtD
Phenylpropanolamine—ADRA2A—testis—prostate cancer	0.000162	0.0233	CbGeAlD
Phenylpropanolamine—Hypotension—Doxorubicin—prostate cancer	0.00016	0.000863	CcSEcCtD
Phenylpropanolamine—Constipation—Epirubicin—prostate cancer	0.000158	0.000854	CcSEcCtD
Phenylpropanolamine—Nausea—Capecitabine—prostate cancer	0.000158	0.000851	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP3A4—prostate cancer	0.000157	0.0188	CrCbGaD
Phenylpropanolamine—Dizziness—Prednisone—prostate cancer	0.000156	0.000844	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—prostate cancer	0.000155	0.000835	CcSEcCtD
Phenylpropanolamine—MAOA—lymph node—prostate cancer	0.000153	0.022	CbGeAlD
Phenylpropanolamine—Dyspnoea—Doxorubicin—prostate cancer	0.000152	0.000823	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—prostate cancer	0.000152	0.000822	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—prostate cancer	0.000152	0.000821	CcSEcCtD
Phenylpropanolamine—Vomiting—Prednisone—prostate cancer	0.00015	0.000811	CcSEcCtD
Phenylpropanolamine—Rash—Prednisone—prostate cancer	0.000149	0.000805	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisone—prostate cancer	0.000149	0.000804	CcSEcCtD
Phenylpropanolamine—Constipation—Doxorubicin—prostate cancer	0.000146	0.00079	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—prostate cancer	0.000141	0.000761	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisone—prostate cancer	0.00014	0.000758	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Epirubicin—prostate cancer	0.000136	0.000735	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP3A4—prostate cancer	0.000133	0.0159	CrCbGaD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—prostate cancer	0.000126	0.00068	CcSEcCtD
Phenylpropanolamine—Dizziness—Epirubicin—prostate cancer	0.000122	0.00066	CcSEcCtD
Phenylpropanolamine—ADRA2A—lymph node—prostate cancer	0.000118	0.0169	CbGeAlD
Phenylpropanolamine—Vomiting—Epirubicin—prostate cancer	0.000118	0.000635	CcSEcCtD
Phenylpropanolamine—Rash—Epirubicin—prostate cancer	0.000117	0.000629	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—prostate cancer	0.000116	0.000629	CcSEcCtD
Phenylpropanolamine—Dizziness—Doxorubicin—prostate cancer	0.000113	0.000611	CcSEcCtD
Phenylpropanolamine—Nausea—Epirubicin—prostate cancer	0.00011	0.000593	CcSEcCtD
Phenylpropanolamine—Vomiting—Doxorubicin—prostate cancer	0.000109	0.000587	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—prostate cancer	0.000108	0.000582	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—prostate cancer	0.000108	0.000582	CcSEcCtD
Phenylpropanolamine—Nausea—Doxorubicin—prostate cancer	0.000102	0.000549	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CAV1—prostate cancer	7.34e-06	3.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	7.31e-06	3.94e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2E1—prostate cancer	7.29e-06	3.92e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—prostate cancer	7.27e-06	3.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	7.26e-06	3.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KDR—prostate cancer	7.26e-06	3.91e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MDM2—prostate cancer	7.24e-06	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NQO1—prostate cancer	7.21e-06	3.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	7.2e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	7.18e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	7.15e-06	3.85e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB2—prostate cancer	7.14e-06	3.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—prostate cancer	7.11e-06	3.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	7.11e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TH—prostate cancer	7.1e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—prostate cancer	7.07e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.06e-06	3.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	7.05e-06	3.8e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CB—prostate cancer	7.04e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	7.04e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—INS—prostate cancer	7.03e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	7.03e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP3A4—prostate cancer	7.03e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—EP300—prostate cancer	7.02e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—prostate cancer	6.99e-06	3.76e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.99e-06	3.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—prostate cancer	6.96e-06	3.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGF2—prostate cancer	6.96e-06	3.74e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1B1—prostate cancer	6.91e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BAD—prostate cancer	6.9e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CREBBP—prostate cancer	6.89e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—prostate cancer	6.88e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—prostate cancer	6.86e-06	3.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	6.82e-06	3.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGF2—prostate cancer	6.8e-06	3.66e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—prostate cancer	6.77e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KDR—prostate cancer	6.74e-06	3.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—prostate cancer	6.71e-06	3.61e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GGT1—prostate cancer	6.69e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	6.69e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APC—prostate cancer	6.69e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JAK2—prostate cancer	6.67e-06	3.59e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1B—prostate cancer	6.61e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGF—prostate cancer	6.61e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS1—prostate cancer	6.61e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NCOA1—prostate cancer	6.59e-06	3.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	6.57e-06	3.54e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—prostate cancer	6.54e-06	3.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	6.53e-06	3.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—prostate cancer	6.53e-06	3.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JAK2—prostate cancer	6.52e-06	3.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MDM2—prostate cancer	6.51e-06	3.5e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP19A1—prostate cancer	6.5e-06	3.5e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—prostate cancer	6.48e-06	3.49e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—prostate cancer	6.47e-06	3.48e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—prostate cancer	6.44e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—prostate cancer	6.42e-06	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	6.42e-06	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BAD—prostate cancer	6.41e-06	3.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	6.39e-06	3.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MDM2—prostate cancer	6.37e-06	3.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	6.33e-06	3.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INS—prostate cancer	6.33e-06	3.41e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—prostate cancer	6.31e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—prostate cancer	6.28e-06	3.38e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—RXRA—prostate cancer	6.27e-06	3.37e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CTNNB1—prostate cancer	6.24e-06	3.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APC—prostate cancer	6.21e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	6.21e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	6.2e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	6.19e-06	3.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—prostate cancer	6.17e-06	3.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGF—prostate cancer	6.14e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	6.14e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—prostate cancer	6.12e-06	3.29e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—prostate cancer	6.12e-06	3.29e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1A—prostate cancer	6.1e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.1e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	6.09e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—prostate cancer	6.09e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—prostate cancer	6.08e-06	3.27e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—prostate cancer	6.04e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—prostate cancer	6.01e-06	3.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	5.96e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—prostate cancer	5.95e-06	3.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	5.94e-06	3.2e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—prostate cancer	5.94e-06	3.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	5.92e-06	3.18e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ITPR1—prostate cancer	5.91e-06	3.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INS—prostate cancer	5.88e-06	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	5.88e-06	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	5.88e-06	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—prostate cancer	5.82e-06	3.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	5.82e-06	3.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.81e-06	3.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—prostate cancer	5.81e-06	3.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	5.81e-06	3.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	5.81e-06	3.13e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EP300—prostate cancer	5.8e-06	3.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—prostate cancer	5.79e-06	3.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	5.76e-06	3.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	5.75e-06	3.1e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	5.75e-06	3.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—prostate cancer	5.7e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—prostate cancer	5.69e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—prostate cancer	5.69e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	5.69e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—prostate cancer	5.67e-06	3.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—prostate cancer	5.66e-06	3.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	5.66e-06	3.05e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—prostate cancer	5.64e-06	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—prostate cancer	5.64e-06	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGF2—prostate cancer	5.63e-06	3.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	5.61e-06	3.02e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TYMS—prostate cancer	5.59e-06	3.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—prostate cancer	5.55e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—prostate cancer	5.55e-06	2.98e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—prostate cancer	5.52e-06	2.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—prostate cancer	5.5e-06	2.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	5.5e-06	2.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—prostate cancer	5.5e-06	2.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	5.49e-06	2.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	5.48e-06	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—prostate cancer	5.47e-06	2.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	5.46e-06	2.94e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—prostate cancer	5.44e-06	2.93e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LPL—prostate cancer	5.42e-06	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	5.41e-06	2.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	5.4e-06	2.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JAK2—prostate cancer	5.39e-06	2.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—prostate cancer	5.38e-06	2.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	5.36e-06	2.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—prostate cancer	5.35e-06	2.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	5.35e-06	2.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—prostate cancer	5.34e-06	2.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	5.29e-06	2.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	5.27e-06	2.83e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1A1—prostate cancer	5.24e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	5.23e-06	2.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—prostate cancer	5.22e-06	2.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EP300—prostate cancer	5.22e-06	2.81e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—prostate cancer	5.19e-06	2.8e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ERCC2—prostate cancer	5.19e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	5.19e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	5.16e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	5.12e-06	2.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EP300—prostate cancer	5.1e-06	2.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—prostate cancer	5.07e-06	2.73e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—prostate cancer	5.06e-06	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—prostate cancer	5.05e-06	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	5.01e-06	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—prostate cancer	4.96e-06	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—prostate cancer	4.95e-06	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—prostate cancer	4.94e-06	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	4.92e-06	2.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—prostate cancer	4.92e-06	2.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	4.91e-06	2.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—prostate cancer	4.89e-06	2.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	4.89e-06	2.63e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—prostate cancer	4.88e-06	2.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—prostate cancer	4.83e-06	2.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	4.82e-06	2.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	4.81e-06	2.59e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARA—prostate cancer	4.79e-06	2.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—prostate cancer	4.79e-06	2.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	4.76e-06	2.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	4.76e-06	2.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	4.71e-06	2.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—prostate cancer	4.7e-06	2.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—EP300—prostate cancer	4.69e-06	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	4.68e-06	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—prostate cancer	4.67e-06	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	4.59e-06	2.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	4.57e-06	2.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—prostate cancer	4.55e-06	2.45e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	4.54e-06	2.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—prostate cancer	4.54e-06	2.44e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAV1—prostate cancer	4.5e-06	2.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	4.47e-06	2.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	4.45e-06	2.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—prostate cancer	4.45e-06	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—prostate cancer	4.45e-06	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	4.44e-06	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—prostate cancer	4.44e-06	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	4.43e-06	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	4.42e-06	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	4.38e-06	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—prostate cancer	4.37e-06	2.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—prostate cancer	4.35e-06	2.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	4.35e-06	2.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	4.32e-06	2.32e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.3e-06	2.32e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—prostate cancer	4.29e-06	2.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	4.26e-06	2.29e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—prostate cancer	4.24e-06	2.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EP300—prostate cancer	4.22e-06	2.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	4.22e-06	2.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—prostate cancer	4.2e-06	2.26e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—prostate cancer	4.15e-06	2.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	4.14e-06	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	4.12e-06	2.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	4.11e-06	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—prostate cancer	4.11e-06	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—prostate cancer	4.11e-06	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—prostate cancer	4.1e-06	2.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	4.01e-06	2.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	4e-06	2.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	3.96e-06	2.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EP300—prostate cancer	3.92e-06	2.11e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INS—prostate cancer	3.88e-06	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	3.86e-06	2.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—prostate cancer	3.81e-06	2.05e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CREBBP—prostate cancer	3.8e-06	2.05e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—prostate cancer	3.8e-06	2.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	3.78e-06	2.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—prostate cancer	3.73e-06	2.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	3.72e-06	2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—prostate cancer	3.68e-06	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	3.68e-06	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	3.67e-06	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—prostate cancer	3.65e-06	1.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.61e-06	1.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	3.6e-06	1.94e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—prostate cancer	3.51e-06	1.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—prostate cancer	3.47e-06	1.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—prostate cancer	3.42e-06	1.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—prostate cancer	3.42e-06	1.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	3.41e-06	1.84e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—prostate cancer	3.4e-06	1.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	3.4e-06	1.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—prostate cancer	3.34e-06	1.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	3.34e-06	1.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	3.16e-06	1.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—prostate cancer	3.15e-06	1.7e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.14e-06	1.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	3.12e-06	1.68e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—prostate cancer	3.11e-06	1.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—prostate cancer	3.08e-06	1.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—prostate cancer	3.02e-06	1.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.9e-06	1.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—prostate cancer	2.83e-06	1.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.81e-06	1.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—prostate cancer	2.77e-06	1.49e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—prostate cancer	2.72e-06	1.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—EP300—prostate cancer	2.59e-06	1.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—prostate cancer	2.57e-06	1.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	2.55e-06	1.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	2.37e-06	1.28e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.92e-06	1.03e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—prostate cancer	1.56e-06	8.42e-06	CbGpPWpGaD
